Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ABOS
STRONG SELLAcumen Pharmaceuticals, Inc. · Healthcare · United States · $154M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. The company concentrates on a highly specific target (amyloid-beta oligomers) with its lead candidate, ACU90, aiming to address the underlying pathology of Alzheimer's. Acumen Pharmaceuticals is a focused biopharmaceutical firm in the high-risk, high-reward Alzheimer's therapeutic space, pursuing innovative disease modification approaches.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -5.02 | -1.06 | -1.08 | -1.71 | -2.00 | — | -1.82 | -1.58 | -1.51 | — |
| Shares | 40.5M | 41.0M | 57.9M | 60.1M | 60.6M | +49.7% | 72.2M | — | — | — |
| Debt | 0 | 0.1M | 28.5M | 28.7M | 31.3M | 568.1% | 31.2M | — | — | — |
| Equity | 225.2M | 188.8M | 267.0M | 181.8M | 70.4M | -25.2% | — | — | — | — |
| Op CF | -18.0M | -35.2M | -43.1M | -86.2M | -115.5M | — | -105.5M | — | — | — |
| Inv CF | -104.1M | 39.2M | -171.7M | 48.0M | 133.9M | — | — | — | — | — |
| Fin CF | 200.5M | 3.9M | 151.8M | 6.9M | -34.0K | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ABOS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ABOS | Acumen Pharmaceuticals, Inc.(you) | $154M | 14 | STRONG SELL |
| CNTN | Canton Strategic Holdings, Inc. | $150M | 14 | STRONG SELL |
| ARCT | Arcturus Therapeutics Holdings Inc. | $157M | 15 | STRONG SELL |
| UNCY | Unicycive Therapeutics, Inc. | $148M | 15 | STRONG SELL |
| KRRO | Korro Bio, Inc. | $153M | 12 | STRONG SELL |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $157M | 12 | STRONG SELL |
| TNYA | Tenaya Therapeutics, Inc. | $168M | 15 | STRONG SELL |
| PYXS | Pyxis Oncology, Inc. | $165M | 13 | STRONG SELL |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | $170M | 15 | STRONG SELL |
| CNTB | Connect Biopharma Holdings Limited | $135M | 13 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%